Introduction and Objective: To date, limited long-term evidence links depressive symptoms to subsequent glycated hemoglobin (HbA1c) trajectories in youth and young adults (YYAs) with youth-onset type 1 diabetes (T1D). We explored the within- and between-person associations of depressive symptoms and changes therein with HbA1c in YYAs with T1D.Methods: We analyzed longitudinal data from the SEARCH for Diabetes in Youth Study and the SEARCH Food Security Cohort Study of 970 YYA with T1D using linear mixed-effect models, adjusting for diabetes duration, sociodemographic and clinical covariates. Depressive symptoms were assessed 3 times between 2016-2022 (t1, t2, and t3) using the Center for Epidemiologic Studies Depression Scale (CES-D; range 0-60), and HbA1c was measured twice at t1 and t3. We computed each participant’s average CES-D score across all timepoints (mean CES-D; between-person measure) and a deviation score (ΔCES-D; within-person measure) defined as the difference between their time-specific CES-D score and their own mean.Results: At t1, 88% of YYA had minimal/mild and 12% had moderate/severe depressive symptoms, and the average HbA1c for all YYA was 9.1%. In unadjusted models, higher mean CES-D over time and higher-than-usual CES-D (ΔCES-D) were associated with higher HbA1c at t3 (β = 0.41, p < 0.001 and β = 0.23, p = 0.008, respectively). After adjustment, each 10-point higher mean CES-D was associated with ~ 0.1 percentage-point higher HbA1c (β = 0.13, p = 0.001), and a 10-point higher CES-D score relative to a participant’s own average (ΔCES-D) was associated with ~ 0.2 percentage-point higher HbA1c at t3 (β = 0.22, p = 0.001).Conclusion: The findings suggest that depressive symptoms are associated with worse HbA1c levels over time, though the magnitude of this is small, highlighting the clinical importance of integrating routine mental health screening and concurrent treatment for depression to optimize glycemic outcomes and improve overall patient care in individuals with diabetes.
A.M. Alfalki: None. E.F. Julceus: None. K. Flory: None. A. Mclain: None. M. Lohman: None. J.A. Mendoza: None. A. Bellatorre: None. F. Malik: None. C. Pihoker: None. A.D. Liese: None.
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (R01DK117461, 1R01DK127208, 1UC4DK108173), and National Institute of General Medical Sciences (T32-GM081740)
Source link
Leave a Reply